$Eli Lilly(LLY.US) (+11% today) continues to capitalize on consumers’ love affair with GLP-1 drugs, with Mounjaro (+126% YoY - diabetes) and Zepbound (+80% YoY - weight loss) both crushing 1Q estimates and helping LLY to beat overall 1Q estimates (Revs +56% YoY vs +49% est) and deliver robust FY’26 rev ($82-$85B vs $82B est) and EPS guides ($35.50-$37 vs $34 est). On deck is LLY’s once daily oral weight loss drug Foundayo which was approved by the FDA for sale on April 1, and at $149/month could be its biggest drug yet.
In recent months, analysts had started to question Lilly’s ability to continue growing at such a rapid pace amid falling prices and political pressure to limit pricing. LLY’s stock slid 23% from late November high of $1,110 to $850 in early April. At a 2026 P/E of 27x vs +15% long-term rev growth and +20% long-term eps growth, LLY still looks compelling.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
